Loading…

US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population

To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patien...

Full description

Saved in:
Bibliographic Details
Published in:Korean journal of radiology 2019, 20(12), , pp.1653-1661
Main Authors: Lim, Hyun Kyung, Cho, Se Jin, Baek, Jung Hwan, Lee, Kang Dae, Son, Chang Woo, Son, Jung Min, Baek, Seon Mi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613
cites cdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613
container_end_page 1661
container_issue 12
container_start_page 1653
container_title Korean journal of radiology
container_volume 20
creator Lim, Hyun Kyung
Cho, Se Jin
Baek, Jung Hwan
Lee, Kang Dae
Son, Chang Woo
Son, Jung Min
Baek, Seon Mi
description To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications. Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths. Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.
doi_str_mv 10.3348/kjr.2019.0192
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_6291565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2328751485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</originalsourceid><addsrcrecordid>eNpdkk1PGzEYhC3UqqS0R67IUi_tYYO_dmP3gBQhSpFSFYVwtrz-ACcbO9i7rdJfX4dQRDlY78GPx57xAHCM0ZhSxk9XyzQmCItxWeQAjAhCdcUpRW_ACBMiqkYQcQje57xEiAjE2TtwSDGvGa7pCPy5vakuB2-sgXNlfHTJPgw26C2ctp3qfQzQxQRn8Xc193kFr9XGd51KW7i436boDfzhdYpaJe1DXKuv8MI5r1URUMHAG-Vsv4U-QAVnKt1ZeB03w174A3jrVJftx6d5BG6_XSzOv1ezn5dX59NZpRkTfeWQVbpthNFaG4FMU7xZopnixjrGjCCE01aQpnWm4caZVteIUWEmpqaiwfQIfNnrhuTkSnsZlX-cd1GukpzOF1eyIQLXTV3Ysz27Gdq1NdqGPqlObpJfF8-PJ__fCf6-6PySJWVKMC0Cn58EUixB5l6ufda2RBZsHLIsFJ_UmPHdXZ9eocs4pFCikGRCOKFYTEihqj1VUs45Wff8GIzkrgGyNEDuGiB3DSj8yUsHz_S_L6d_AdQJreE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728231972</pqid></control><display><type>article</type><title>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Lim, Hyun Kyung ; Cho, Se Jin ; Baek, Jung Hwan ; Lee, Kang Dae ; Son, Chang Woo ; Son, Jung Min ; Baek, Seon Mi</creator><creatorcontrib>Lim, Hyun Kyung ; Cho, Se Jin ; Baek, Jung Hwan ; Lee, Kang Dae ; Son, Chang Woo ; Son, Jung Min ; Baek, Seon Mi</creatorcontrib><description>To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications. Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths. Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.</description><identifier>ISSN: 1229-6929</identifier><identifier>EISSN: 2005-8330</identifier><identifier>DOI: 10.3348/kjr.2019.0192</identifier><identifier>PMID: 31854153</identifier><language>eng</language><publisher>Korea (South): The Korean Society of Radiology</publisher><subject>Ablation ; Biopsy ; Electrodes ; Laboratories ; Local anesthesia ; Metastasis ; Patients ; Surgery ; Thyroid ; Thyroid cancer ; Tumors ; Ultrasonic imaging ; 방사선과학</subject><ispartof>Korean Journal of Radiology, 2019, 20(12), , pp.1653-1661</ispartof><rights>Copyright © 2019 The Korean Society of Radiology.</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2019 The Korean Society of Radiology 2019 The Korean Society of Radiology</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</citedby><cites>FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</cites><orcidid>0000-0001-6450-7554 ; 0000-0001-8075-0730 ; 0000-0003-2319-3135</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2728231972/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2728231972?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31854153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002531483$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Hyun Kyung</creatorcontrib><creatorcontrib>Cho, Se Jin</creatorcontrib><creatorcontrib>Baek, Jung Hwan</creatorcontrib><creatorcontrib>Lee, Kang Dae</creatorcontrib><creatorcontrib>Son, Chang Woo</creatorcontrib><creatorcontrib>Son, Jung Min</creatorcontrib><creatorcontrib>Baek, Seon Mi</creatorcontrib><title>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</title><title>Korean journal of radiology</title><addtitle>Korean J Radiol</addtitle><description>To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications. Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths. Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.</description><subject>Ablation</subject><subject>Biopsy</subject><subject>Electrodes</subject><subject>Laboratories</subject><subject>Local anesthesia</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Surgery</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><subject>방사선과학</subject><issn>1229-6929</issn><issn>2005-8330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkk1PGzEYhC3UqqS0R67IUi_tYYO_dmP3gBQhSpFSFYVwtrz-ACcbO9i7rdJfX4dQRDlY78GPx57xAHCM0ZhSxk9XyzQmCItxWeQAjAhCdcUpRW_ACBMiqkYQcQje57xEiAjE2TtwSDGvGa7pCPy5vakuB2-sgXNlfHTJPgw26C2ctp3qfQzQxQRn8Xc193kFr9XGd51KW7i436boDfzhdYpaJe1DXKuv8MI5r1URUMHAG-Vsv4U-QAVnKt1ZeB03w174A3jrVJftx6d5BG6_XSzOv1ezn5dX59NZpRkTfeWQVbpthNFaG4FMU7xZopnixjrGjCCE01aQpnWm4caZVteIUWEmpqaiwfQIfNnrhuTkSnsZlX-cd1GukpzOF1eyIQLXTV3Ysz27Gdq1NdqGPqlObpJfF8-PJ__fCf6-6PySJWVKMC0Cn58EUixB5l6ufda2RBZsHLIsFJ_UmPHdXZ9eocs4pFCikGRCOKFYTEihqj1VUs45Wff8GIzkrgGyNEDuGiB3DSj8yUsHz_S_L6d_AdQJreE</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Lim, Hyun Kyung</creator><creator>Cho, Se Jin</creator><creator>Baek, Jung Hwan</creator><creator>Lee, Kang Dae</creator><creator>Son, Chang Woo</creator><creator>Son, Jung Min</creator><creator>Baek, Seon Mi</creator><general>The Korean Society of Radiology</general><general>대한영상의학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0001-6450-7554</orcidid><orcidid>https://orcid.org/0000-0001-8075-0730</orcidid><orcidid>https://orcid.org/0000-0003-2319-3135</orcidid></search><sort><creationdate>20191201</creationdate><title>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</title><author>Lim, Hyun Kyung ; Cho, Se Jin ; Baek, Jung Hwan ; Lee, Kang Dae ; Son, Chang Woo ; Son, Jung Min ; Baek, Seon Mi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ablation</topic><topic>Biopsy</topic><topic>Electrodes</topic><topic>Laboratories</topic><topic>Local anesthesia</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Surgery</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><topic>방사선과학</topic><toplevel>online_resources</toplevel><creatorcontrib>Lim, Hyun Kyung</creatorcontrib><creatorcontrib>Cho, Se Jin</creatorcontrib><creatorcontrib>Baek, Jung Hwan</creatorcontrib><creatorcontrib>Lee, Kang Dae</creatorcontrib><creatorcontrib>Son, Chang Woo</creatorcontrib><creatorcontrib>Son, Jung Min</creatorcontrib><creatorcontrib>Baek, Seon Mi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Korean journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Hyun Kyung</au><au>Cho, Se Jin</au><au>Baek, Jung Hwan</au><au>Lee, Kang Dae</au><au>Son, Chang Woo</au><au>Son, Jung Min</au><au>Baek, Seon Mi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population</atitle><jtitle>Korean journal of radiology</jtitle><addtitle>Korean J Radiol</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>20</volume><issue>12</issue><spage>1653</spage><epage>1661</epage><pages>1653-1661</pages><issn>1229-6929</issn><eissn>2005-8330</eissn><abstract>To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications. Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths. Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.</abstract><cop>Korea (South)</cop><pub>The Korean Society of Radiology</pub><pmid>31854153</pmid><doi>10.3348/kjr.2019.0192</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6450-7554</orcidid><orcidid>https://orcid.org/0000-0001-8075-0730</orcidid><orcidid>https://orcid.org/0000-0003-2319-3135</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1229-6929
ispartof Korean Journal of Radiology, 2019, 20(12), , pp.1653-1661
issn 1229-6929
2005-8330
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_6291565
source Publicly Available Content Database; PubMed Central(OpenAccess)
subjects Ablation
Biopsy
Electrodes
Laboratories
Local anesthesia
Metastasis
Patients
Surgery
Thyroid
Thyroid cancer
Tumors
Ultrasonic imaging
방사선과학
title US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T00%3A15%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=US-Guided%20Radiofrequency%20Ablation%20for%20Low-Risk%20Papillary%20Thyroid%20Microcarcinoma:%20Efficacy%20and%20Safety%20in%20a%20Large%20Population&rft.jtitle=Korean%20journal%20of%20radiology&rft.au=Lim,%20Hyun%20Kyung&rft.date=2019-12-01&rft.volume=20&rft.issue=12&rft.spage=1653&rft.epage=1661&rft.pages=1653-1661&rft.issn=1229-6929&rft.eissn=2005-8330&rft_id=info:doi/10.3348/kjr.2019.0192&rft_dat=%3Cproquest_nrf_k%3E2328751485%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c449t-f0eacb69dcccd90d6330e2c4a8def44d92283b926bfd68dfdbc50439d7d539613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2728231972&rft_id=info:pmid/31854153&rfr_iscdi=true